If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Omvoh ® (mirikizumab-mrkz) injection
300 mg/15 mL, 100 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is Omvoh® (mirikizumab-mrkz) for ulcerative colitis citrate-free?
A citrate-free formulation of mirikizumab-mrkz for the treatment of ulcerative colitis has been approved.
Citrate-Free Mirikizumab for Ulcerative Colitis
The US Food and Drug Administration has recently approved a citrate-free formulation of mirikizumab-mrkz for subcutaneous administration to treat ulcerative colitis. This new formulation, which will be available as a prefilled syringe and a prefilled pen, will be available by the second half of this year.1,2
Enclosed Prescribing Information
References
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
Date of Last Review: January 30, 2025